300026.SHE Tianjin Chase Sun Pharmaceutical Co Ltd
- Market cap
- CNY 9.22B
- P/E
- 307.0x
- P/B
- 1.08x
- ROE
- 0.5%
- Dividend yield
- 1.49%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is 300026.SHE undervalued?
Graham numberThe Graham number of Tianjin Chase Sun Pharmaceutical Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tianjin Chase Sun Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Tianjin Chase Sun Pharmaceutical Co Ltd yet.
Tianjin Chase Sun Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tianjin Chase Sun Pharmaceutical Co Ltd
Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and sale of various pharmaceutical products in China. The company offers traditional Chinese medicine formula granules; finished drugs, including xuebijing injections, low molecular weight heparin calcium injections, moxifloxacin hydrochloride sodium chloride injections, enoxaparin sodium injections, nadronexacin calcium injections, fasudil hydrochloride injections, ketorheic acid trom…
Full company profileTianjin Chase Sun Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tianjin Chase Sun Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.35B | 3.87B | 3.37B | 4.22B | 5.00B | 6.49B | 7.67B | 6.65B | 6.11B | 5.78B | 3.95B |
| Gross Profit | 2.77B | 2.90B | 2.44B | 2.97B | 3.35B | 3.63B | 4.40B | 3.82B | 3.28B | 2.99B | 2.23B |
| Operating Income | 579M | 733M | 525M | 292M | 483M | 654M | 875M | 713M | 489M | 35.4M | 133M |
| EBITDA | 686M | 899M | 701M | 469M | 656M | 913M | 1.13B | 1.05B | 966M | 387M | 91.0M |
| Net Income | 535M | 659M | 451M | 211M | 403M | 573M | 687M | 624M | 507M | 21.5M | 44.7M |
| EPS | 0.20 | 0.22 | 0.15 | 0.07 | 0.14 | 0.19 | 0.23 | 0.21 | 0.17 | 0.01 | 0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 6.47B | 7.28B | 7.43B | 7.48B | 8.43B | 10.2B | 11.6B | 12.6B | 11.8B | 11.2B | 10.1B |
| Total Liabilities | 1.18B | 1.24B | 920M | 908M | 1.36B | 2.79B | 3.65B | 4.17B | 2.97B | 2.37B | 1.42B |
| Shareholders' Equity | 5.27B | 5.93B | 6.35B | 6.41B | 6.79B | 7.19B | 7.77B | 8.29B | 8.71B | 8.64B | 8.57B |
| Cash & Short-term Investments | 1.39B | 1.37B | 1.35B | 1.21B | 988M | 1.13B | 1.32B | 1.21B | 1.57B | 1.31B | 1.70B |
| Total Debt | 317M | 497M | 270M | 216M | 370M | 1.16B | 1.96B | 2.09B | 1.34B | 657M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 121M | 448M | 742M | 388M | 216M | 197M | 392M | 745M | 1.53B | 852M | - |
| Capital Expenditure | 223M | 416M | 383M | 295M | 591M | 564M | 677M | 770M | 347M | 193M | 93.3M |
| Free Cash Flow | -102M | 32.6M | 359M | 93.3M | -375M | -367M | -286M | -24.9M | 1.18B | 659M | 713M |
| Ratios | |||||||||||
| ROE | 10.2% | 11.1% | 7.1% | 3.3% | 5.9% | 8.0% | 8.8% | 7.5% | 5.8% | 0.2% | 0.5% |
| ROA | 8.3% | 9.0% | 6.1% | 2.8% | 4.8% | 5.6% | 5.9% | 4.9% | 4.3% | 0.2% | 0.4% |
| Net Profit Margin | 16.0% | 17.0% | 13.4% | 5.0% | 8.0% | 8.8% | 9.0% | 9.4% | 8.3% | 0.4% | 1.1% |
| Debt to Equity | 0.06x | 0.08x | 0.04x | 0.03x | 0.05x | 0.16x | 0.25x | 0.25x | 0.15x | 0.08x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tianjin Chase Sun Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.49%
- Forward dividend
- 0.01 CNY
- Payout ratio
- 638.7%
- Ex-dividend date
- Jul 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2024 | CNY 137M | 0.06 | 638.7% |
| 2023 | CNY 155M | 0.05 | 30.5% |
| 2022 | CNY 120M | 0.04 | 19.2% |
| 2021 | CNY 120M | 0.04 | 17.5% |
| 2020 | CNY 150M | 0.05 | 26.2% |
| 2019 | CNY 59.5M | 0.02 | 14.8% |
| 2018 | CNY 70.9M | 0.02 | 33.6% |
| 2017 | CNY 94.3M | 0.03 | 20.9% |
| 2016 | CNY 72.9M | 0.02 | 11.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 30:10 on Oct 26, 2016.
Who owns Tianjin Chase Sun Pharmaceutical Co Ltd
- Insiders 42.44%
- Institutions 1.58%
- Public & others 55.98%
- Shares outstanding 3.00B
- Free float 2.28B
Tianjin Chase Sun Pharmaceutical Co Ltd company profile
- Company name
- Tianjin Chase Sun Pharmaceutical Co Ltd
- Ticker
- 300026.SHE
- ISIN
- CNE100000GF1
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Oct 30, 2009
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,852
- Fiscal year end
- December
- Address
- Building B01, Entrepreneurship Headquarters Base, Tianjin, China, 301700
- Phone
- 86 22 5962 3160
- Website
- chasesun.cn
About Tianjin Chase Sun Pharmaceutical Co Ltd
Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and sale of various pharmaceutical products in China. The company offers traditional Chinese medicine formula granules; finished drugs, including xuebijing injections, low molecular weight heparin calcium injections, moxifloxacin hydrochloride sodium chloride injections, enoxaparin sodium injections, nadronexacin calcium injections, fasudil hydrochloride injections, ketorheic acid tromethamine injections, ibanoxetine sodium injections, Qingfei Sanjie pills, and Ping Wan anti-cancer pills; raw materials and excipients, such as pharmaceutical excipients, active pharmaceutical ingredients (APIs), and food additives; medical devices, including oxygen concentrators and portable oxygen concentrators; medical and health services; and intelligent supply chain services for pharmaceuticals and medical devices. It also provides chemical reagents, Western patent medicines, enteric casings, heparin sodium, food, beverages, seasonings, tea, candies, and traditional Chinese medicine decoction pieces; pharmaceutical equipment and self-owned housing leasing; pharmaceutical product and medical device research and development; technology consulting, transfer, and promotion; health management, business management, nutritional health, and health information consulting; wholesale and retail of electronic products; import and export of goods and technology; biopharmaceutical project management; project investment; technical service development, transfer, and consulting; consumer electronics and sporting goods sales; computer software and hardware development; general hospital services; nursing services for the elderly and disabled; medical management; diagnosis and treatment; and medical data research activities. The company exports its products to approximately 50 countries and regions. Tianjin Chase Sun Pharmaceutical Co.,Ltd was founded in 1996 and is headquartered in Tianjin, China.
Tianjin Chase Sun Pharmaceutical Co Ltd management
6- Mr. Wu Jun LanVice Chairman & GM · born 1975
- Mr. Jiaping DanCFO, Chief Accountant & Non-Independent Director · born 1981
- Ms. Yi YangDirector & Secretary · born 1990
- Mr. Rui Qiang ChenDeputy General Manager · born 1977
- Mr. Kun ZhangDeputy General Manager · born 1976
- Mr. Xiao Zhong LuDeputy General Manager · born 1980